Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Dialogues Clin Neurosci. 2010;12(3):359-82.

Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.

Author information

  • 1Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA. joseph_coyle@hms.harvard.edu

Abstract

All current drugs approved to treat schizophrenia appear to exert their antipsychotic effects through blocking the dopamine D2 receptor. Recent meta-analyses and comparative efficacy studies indicate marginal differences in efficacy of newer atypical antipsychotics and the older drugs, and little effects on negative and cognitive symptoms. This review integrates findings from postmortem, imaging, and drug-challenge studies to elucidate a corticolimbic "pathologic circuit" in schizophrenia that may be particularly relevant to the negative symptoms and cognitive impairments of schizophrenia. Potential sites for pharmacologic intervention targeting glutatatergic, GABAergic, and cholinergic neurotransmission to treat these symptoms of schizophrenia are discussed.

PMID:
20954431
[PubMed - indexed for MEDLINE]
PMCID:
PMC3181979
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Les Laboratoires Servier Icon for PubMed Central
    Loading ...
    Write to the Help Desk